- Trials with a EudraCT protocol (78)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
78 result(s) found for: leucovorin calcium.
Displaying page 1 of 4.
| EudraCT Number: 2004-005215-29 | Sponsor Protocol Number: 03-CoFactor | Start Date*: 2005-06-03 | |||||||||||
| Sponsor Name:ADVENTRX Pharmaceuticals Inc | |||||||||||||
| Full Title: A Multi-Center, Open Label, Parallel Group, Randomised, Phase IIB Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-FU versus Leucovorin and 5-FU in Subjects with Metastatic Colo... | |||||||||||||
| Medical condition: Metastatic Colorectal Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2004-004901-12 | Sponsor Protocol Number: SFOLFOX/SFOLFIRI vs FOLFOX/FOLFIRI | Start Date*: 2005-05-13 | |||||||||||
| Sponsor Name:TEVA Pharma Belgium | |||||||||||||
| Full Title: Phase II randomized study of Combined Infusional Leucovorin Sodium and 5-FU Versus the Classical Sequential administration of Leucovorin Calcium followed by 5-FU both in combination with standard ... | |||||||||||||
| Medical condition: Histologically confirmed adenocarcinoma of the colon or the rectum and unresectable metastases or advanced locoregional disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-004687-30 | Sponsor Protocol Number: MM-398-07-03-01 | Start Date*: 2012-03-06 | |||||||||||||||||||||
| Sponsor Name:Merrimack Pharmaceuticals Inc. | |||||||||||||||||||||||
| Full Title: NAPOLI 1: A Randomized, Open Label Phase 3 Study of MM-398, with or without 5-Fluorouracil and Leucovorin, versus 5-Fluorouracil and Leucovorin, in Patients with Metastatic Pancreatic Cancer Who h... | |||||||||||||||||||||||
| Medical condition: Metastatic Pancreatic Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: HU (Completed) CZ (Completed) GB (Completed) IT (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2004-001155-11 | Sponsor Protocol Number: OSI-904-202 | Start Date*: 2005-02-25 | |||||||||||
| Sponsor Name:OSI Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Randomized, Open Label, Phase II Study of OSI-7904L versus 5-FU/LV as First-Line Treatment in Patients with Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract | |||||||||||||
| Medical condition: Unresectable, locally advanced or metastatic adenocarcinoma of the biliary tract | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-005141-16 | Sponsor Protocol Number: NL75539.078.20 | Start Date*: 2021-06-23 | |||||||||||
| Sponsor Name:Erasmus MC | |||||||||||||
| Full Title: Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study. | |||||||||||||
| Medical condition: non-metastatic resectable pancreatic cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-000526-23 | Sponsor Protocol Number: A6181049 | Start Date*: 2005-08-30 |
| Sponsor Name:Pfizer Inc. | ||
| Full Title: A PHASE 1 STUDY OF SU011248 IN COMBINATION WITH FOLFIRI (IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN) IN PATIENTS WITH METASTATIC COLORECTAL CANCER | ||
| Medical condition: Metastatic colorectal cancer. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-001195-36 | Sponsor Protocol Number: ICORG 06-39/ ECOG E5202 | Start Date*: 2007-05-04 | |||||||||||
| Sponsor Name:All Ireland Cooperative Oncology Research Group (ICORG) | |||||||||||||
| Full Title: A Randomised Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Det... | |||||||||||||
| Medical condition: Stage II colon cancer. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-001459-17 | Sponsor Protocol Number: NuTide:323 | Start Date*: 2023-03-27 | |||||||||||
| Sponsor Name:NuCana plc | |||||||||||||
| Full Title: A randomised, open-label, Phase II, dose/schedule optimisation study of NUC-3373/leucovorin/irinotecan plus bevacizumab (NUFIRI-bev) versus 5-FU/leucovorin/irinotecan plus bevacizumab (FOLFIRI-bev)... | |||||||||||||
| Medical condition: Relapsed, unresectable, histologically or cytologically confirmed metastatic adenocarcinoma of colon or rectum with radiologically measurable disease. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) DE (Prematurely Ended) IT (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-000331-14 | Sponsor Protocol Number: ICORG 05-02/NSABP C-08 | Start Date*: 2005-04-08 |
| Sponsor Name:All Ireland Cooperative Oncology Research Group | ||
| Full Title: A phase III clinical trial comparing infusional 5-Fluorouracil (5-FU), Leucovorin and Oxaliplatin (mFOLFOX -6) every 2 weeks with Bevacizumab to the same regimen without Bevacizumab for the treatme... | ||
| Medical condition: Resected stage II or stage III adenocarcinoma of the colon | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-018754-13 | Sponsor Protocol Number: FLOT4 | Start Date*: Information not available in EudraCT |
| Sponsor Name:Krankenhaus Nordwest GmbH | ||
| Full Title: A randomized multicenter Phase II/III Study comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) versus Epirubicin, Cisplatin and 5-FU (ECF) in patients with locally advanced resectable ad... | ||
| Medical condition: locally advanced resectable adenocarcinoma of the esophagogastreal junction or the stomach | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-000686-19 | Sponsor Protocol Number: MO05/6844 | Start Date*: 2005-04-28 |
| Sponsor Name:University of Leeds | ||
| Full Title: PACT (Patient Preferences in Adjuvant Colorectal Cancer Therapy) - A randomised crossover clinical trial comparing Bolus Fluorouracil/Leucovorin to Capecitabine as treatment for moderate to high ri... | ||
| Medical condition: Moderate to high risk resected colorectal cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-000327-15 | Sponsor Protocol Number: XL119-001 | Start Date*: 2004-11-25 | |||||||||||
| Sponsor Name:Exelixis, Inc. | |||||||||||||
| Full Title: A Phase 3 Multicenter, Single-Blind, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) plus Leucovorin (LV) in Subjects with Advanced Bilary Tumors Not Amenable to Coventional Surgery | |||||||||||||
| Medical condition: Advanced Bilary Tract Tumours: Gall bladder cancer and Cholangiocarcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) GB (Prematurely Ended) BE (Completed) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-002036-17 | Sponsor Protocol Number: NL61961.078.17 | Start Date*: 2018-03-06 | |||||||||||
| Sponsor Name:Erasmus Medical Center | |||||||||||||
| Full Title: THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDERLINE) RESECTABLE PANCREATIC CANCER | |||||||||||||
| Medical condition: (borderline) resectable pancreatic cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-001288-99 | Sponsor Protocol Number: C4221015 | Start Date*: 2020-11-26 | |||||||||||
| Sponsor Name:Pfizer Inc. | |||||||||||||
| Full Title: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND C... | |||||||||||||
| Medical condition: Colorectal cancer (BRAF V600E-mutant mCRC) | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NO (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Ongoing) DE (Ongoing) FR (Not Authorised) BE (Trial now transitioned) SE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-000325-21 | Sponsor Protocol Number: A6181122 | Start Date*: 2007-05-02 | |||||||||||
| Sponsor Name:Pfizer Inc. - 235 East 42nd Street - New York - 10017 | |||||||||||||
| Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFIRI) AS FIRST LINE TREATMENT | |||||||||||||
| Medical condition: first-line treatment of patients with metastatic colorectal cancer. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) IE (Completed) DE (Completed) AT (Completed) ES (Completed) HU (Completed) BE (Completed) PT (Completed) CZ (Completed) GB (Completed) BG (Completed) SK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-004048-27 | Sponsor Protocol Number: 849-010 | Start Date*: 2022-02-09 | |||||||||||
| Sponsor Name:Mirati Therapeutics, Inc. | |||||||||||||
| Full Title: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Stan... | |||||||||||||
| Medical condition: Advanced Colorectal Cancer with KRAS G12C Mutation | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) PT (Trial now transitioned) FI (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-005022-23 | Sponsor Protocol Number: D4200C00047 | Start Date*: 2007-03-22 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase II, Double-Blind, Placebo Controlled, Randomised Study To Assess The Efficacy And Safety Of 2 Doses Of ZACTIMA (ZD6474) In Combination With FOLFOX vs FOLFOX Alone For The Treatment Of Color... | |||||||||||||
| Medical condition: Colorectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) HU (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-004154-41 | Sponsor Protocol Number: ISO-CC-007 | Start Date*: 2018-11-07 | |||||||||||
| Sponsor Name:Isofol Medical AB | |||||||||||||
| Full Title: A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5 fluorouracil, oxaliplatin, and bevacizumab in patients wi... | |||||||||||||
| Medical condition: First line advanced Colorectal patients eligible for treatment with 5-FU, oxaliplatin, and bevacizumab. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) AT (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-003440-66 | Sponsor Protocol Number: D8480C00013 | Start Date*: 2006-09-11 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizuma... | |||||||||||||
| Medical condition: This is a Phase II / III trial in Patients with Previously Untreated Metastatic Colorectal Cancer. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) AT (Completed) CZ (Completed) DE (Completed) SK (Completed) HU (Completed) IT (Completed) GB (Completed) FI (Completed) LV (Completed) MT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-003585-14 | Sponsor Protocol Number: D-US-60010-001 | Start Date*: 2020-04-08 | |||||||||||
| Sponsor Name:Ipsen Bioscience, Inc. | |||||||||||||
| Full Title: An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not prev... | |||||||||||||
| Medical condition: Previously Untreated, Metastatic Pancreatic Adenocarcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) HU (Completed) BE (Completed) CZ (Completed) AT (Completed) FR (Completed) PT (Completed) GR (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.